- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Eleanor Perfetto, PhD, MS, Describes the Importance of Comparative Effectiveness Research (CER) and the CER Collaborative Initiative
Eleanor Perfetto, PhD, MS, professor, pharmaceutical health services research, School of Pharmacy, University of Maryland, says that incorporating comparative effectiveness research (CER) into pharmacy curriculums is important for the next generation of pharmacists.
Eleanor Perfetto, PhD, MS, professor, pharmaceutical health services research, School of Pharmacy, University of Maryland, says that incorporating comparative effectiveness research (CER) into pharmacy curriculums is important for the next generation of pharmacists.
Understanding comparative effectiveness is essential for literature competency and evaluating research studies. A rigorous program, such as the one offered at the University of Maryland, will help students avoid learning “on the fly” as practitioners, and help them make evidence-based decisions.
Dr Perfetto also discusses the CER Collaborative Initiative. The group is comprised of researchers from 3 organizations including the Academy of Managed Care Pharmacy, International Society for Pharmacoeconomics and Outcomes Research, and the National Pharmaceutical Council. The tools and resources they develop help practitioners to appropriately utilize evidence-based research from studies like those that appear in AJMC.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More
